FDA approves Novo Nordisk's higher-dose Wegovy in competitive market push. The 7.2-milligram formulation gained approval through an expedited FDA voucher program, delivering 20.7 percent average body weight loss in clinical trials versus 17.5 percent for lower doses. The Danish pharmaceutical giant faces intensifying competition from Eli Lilly and mounting pressure from Trump administration drug cost-cutting initiatives. Novo plans April US launch of the single-dose pen version, with pricing details forthcoming. The company previously introduced an oral alternative to strengthen its market position. Regulatory decisions on the pen formulation in UK and EU markets are expected in the second half of 2026. This approval represents a strategic move to regain market share in the lucrative obesity treatment sector.
